Germany's Bayer eyes sex drug for older women
Thursday 07 October 2010
German pharmaceutical giant Bayer signed a deal Tuesday with Quebec's EndoCeutics to develop a new treatment for post-menopausal women experiencing vaginal atrophy that can lead to sexual dysfunction.
The future treatment - provisionally dubbed Vaginorm - will boost the steroid DHEA in women's bodies; DHEA levels go lower naturally as people age.
In women's case, that can mean vaginal tissues change somewhat and become drier, which can lead to uncomfortable or painful sexual relations.
The deal covers the Phase III clinical development of the product and bringing it to market. It could mean as much as 330 million dollars in research spending for Canada, the companies said in a statement.
With the baby boomer generation nearing retirement age, pharmaceutical companies are keen to find an illusive treatment for sexual dysfunction in older women to match the success of Viagra and other drugs for their male counterparts.
EndoCeutics said it hoped to improve the quality of life of some 360 million women worldwide aged 50 or older who it said have vaginal atrophy or dryness.
Life & Style blogs
The mother who never gave up on her child abused by the Oxford child sex ring
Britain scrapes into top 25 countries in the world to be a mother in Save the Children report
How to gain confidence and maximise your sexual potential
What do the emoji on Snapchat mean?
The 12 most sexually satisfied countries in the world revealed
- 2 General Election 2015: 14-year-old boy asks Nick Clegg – 'can you kill Katie Hopkins?'
- 3 University student in court for allegedly covering housemates' food in window cleaner and spit
- 4 Ryan Gosling posts tribute to 'Ryan Gosling Won't Eat His Cereal' creator Ryan McHenry
£13676.46 - £16411.61 per annum + OTE: SThree: SThree Trainee Recruitment Cons...
£18000 - £22000 per annum + training: Ashdown Group: Business and Marketing Gr...
£20000 - £25000 per annum + Commission: SThree: Are you great at building rela...
£20000 - £22000 per annum + excellent benefits: Ashdown Group: Application Sup...